Skip to main content
About
Contact
Subscribe
e-Edition
Make Home Page
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Twitter
Toggle navigation
Site search
Search
Home
Contact Us
Advertise
Subscription Services
Promote Your Event
Submission Forms
News
Local News
National
World
Archives
Sports
Local Sports
National Sports
Business
Local Business
National Business
Technology
Markets & Stocks
Opinion
Columns
Editorials
Letters To The Editor
Polls
Thumbs
A & E
Local Entertainment
Art Scene
Music Scene
Theatre Scene
Book Reviews
Movie Reviews
TV Listings
Local Events
What To Do
Life
Health
Travel
Oddities
Community Directory
Community Service
Rescue Me
Other
Magazines
Fall Home Improvements
Women
Home & Realty
Outdoor Guide
Premier Home Style Tour 2024
Spring Home & Garden Show
Spring on the Road
Spring Wellness
Classifieds
Place Ad
Careers
Tenders
Weather
Obituaries
Parcel Pickup
2024 Readersâ Choice
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Aditxt, Inc.
< Previous
1
2
Next >
Aditxt's Subsidiary Adimune Successfully Completes Preclinical Efficacy and Safety Studies for Its Immune Modulation Therapeutic ADI Platform, Advancing Toward First-in-Human Clinical Trials
December 12, 2024
From
Aditxt, Inc.
Via
Business Wire
Tickers
ADTX
APLIF
EVFM
OTC
Aditxt Provides Update on Equity Line of Credit, ATM Usage, and Outstanding Number of Shares
November 08, 2024
From
Aditxt, Inc.
Via
Business Wire
Tickers
ADTX
APLIF
EVFM
OTC
Aditxt’s Target Acquisition Appili Therapeutics Announces Results of Special Meeting of Shareholders
November 07, 2024
From
Aditxt, Inc.
Via
Business Wire
Tickers
ADTX
APLIF
OTC
TSX:APLI
Aditxt Acquisition Target Evofem Biosciences Secures Investor Support Through Voting Agreements for Merger with Aditxt's Subsidiary Adifem
November 06, 2024
From
Aditxt, Inc.
Via
Business Wire
Tickers
ADTX
APLIF
EVFM
OTC
Aditxt’s Target Acquisition Appili Therapeutics Announces Alignment with FDA on Development Requirements for ATI-1801 Topical Antiparasitic Product NDA Submission
October 31, 2024
From
Aditxt, Inc.
Via
Business Wire
Tickers
ADTX
APLIF
OTC
TSX:APLI
Aditxt To Host Virtual Stakeholder Update and Q&A Session on Friday, November 1, 2024, at 11:30 AM Eastern Time
October 30, 2024
From
Aditxt, Inc.
Via
Business Wire
Tickers
ADTX
APLIF
EVFM
OTC
Sylvia Hermina Joins Aditxt’s Board of Directors, Elevating Leadership with Broader Perspectives
October 29, 2024
From
Aditxt, Inc.
Via
Business Wire
Tickers
ADTX
APLIF
EVFM
OTC
Aditxt Completes Final Equity Investment and Key Milestone Under the Amended and Restated Merger Agreement with Evofem
October 28, 2024
From
Aditxt, Inc.
Via
Business Wire
Tickers
ADTX
APLIF
EVFM
OTC
Aditxt to Host a Virtual Fireside Chat with Aditxt CEO Amro Albanna and Evofem CEO Saundra Pelletier, Moderated by MD & Media Personality Dr. Drew Pinsky, on October 28, 2024, at 11:30 AM Eastern Time
October 21, 2024
From
Aditxt, Inc.
Via
Business Wire
Tickers
ADTX
EVFM
Aditxt’s Acquisition Target Appili Therapeutics Will Hold a Special Meeting of Shareholders on November 6, 2024, to Vote on the Transaction and Secure Appili’s Shareholder Approval
October 10, 2024
From
Aditxt, Inc.
Via
Business Wire
Tickers
ADTX
APLIF
OTC
TSX:APLI
Aditxt To Host Stakeholder Update and Q&A Session on Friday, October 11, 2024, at 11:30 AM Eastern Daylight Time
October 09, 2024
From
Aditxt, Inc.
Via
Business Wire
Tickers
ADTX
Aditxt Completes Third Parent Equity Investment Under Amended and Restated Merger Agreement With Evofem
October 08, 2024
From
Aditxt, Inc.
Via
Business Wire
Tickers
ADTX
EVFM
Aditxt Delivers Shareholder Update and 2024 Year-End Plan
October 03, 2024
From
Aditxt, Inc.
Via
Business Wire
Tickers
ADTX
APLIF
EVFM
OTC
Aditxt, Inc. (NASDAQ: ADTX) Announces 1-for-40 Reverse Stock Split Effective at the Open of Trading on October 2, 2024
September 27, 2024
From
Aditxt, Inc.
Via
Business Wire
Tickers
ADTX
Evofem Biosciences Files Preliminary Proxy for Stockholder Approval of the Acquisition by Aditxt
September 24, 2024
From
Aditxt, Inc.
Via
Business Wire
Tickers
ADTX
EVFM
Aditxt’s Subsidiary Pearsanta to Collaborate with Evofem Biosciences for Targeted U.S. Launch of Endometriosis Diagnostic in Mid-2025
September 20, 2024
From
Aditxt, Inc.
Via
Business Wire
Tickers
ADTX
EVFM
Aditxt and Evofem Sign Second Amendment to Amended and Restated Merger Agreement, Target Closing of Acquisition in Fourth Quarter of 2024
September 09, 2024
From
Aditxt, Inc.
Via
Business Wire
Tickers
ADTX
EVFM
Aditxt Subsidiary Pearsanta Submits a Grant Application Seeking to Advance Clinical Trials for Mitomic® Prostate Test, Targeting Early Detection in High-Risk Patients
September 04, 2024
From
Aditxt, Inc.
Via
Business Wire
Tickers
ADTX
Aditxt to Present at the H.C. Wainwright 26th Annual Global Investment Conference September 9th-11th, 2024
August 29, 2024
From
Aditxt, Inc.
Via
Business Wire
Tickers
ADTX
APLIF
EVFM
OTC
Aditxt’s Precision Health Subsidiary, Pearsanta, Appoints Christopher Mitton as President as it Seeks to Complete Clinical Validation Studies for its Mitomic® Endometriosis Test (MET™) and Mitomic® Prostate Test (MPT™)
August 26, 2024
From
Aditxt, Inc.
Via
Business Wire
Tickers
ADTX
Aditxt Announces Third Amendment to Arrangement Agreement with Appili Therapeutics
August 21, 2024
From
Aditxt, Inc.
Via
Business Wire
Tickers
ADTX
APLIF
OTC
TSX:APLI
Aditxt Announces the Successful Passage of all Proposals at Recent Annual Shareholders’ Meeting, Setting the Stage for 2024 and 2025 Strategic Plans
August 13, 2024
From
Aditxt, Inc.
Via
Business Wire
Tickers
ADTX
Aditxt Announces Closing of $1.2 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
August 09, 2024
From
Aditxt, Inc.
Via
Business Wire
Tickers
ADTX
Aditxt Announces $1.2 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
August 09, 2024
From
Aditxt, Inc.
Via
Business Wire
Tickers
ADTX
Aditxt Subsidiary Pearsanta Seeks Clinical Trial Translational Endpoints Research Award for Early Detection of Ovarian Cancer
August 07, 2024
From
Aditxt, Inc.
Via
Business Wire
Tickers
ADTX
Aditxt Signs Second Amendment to the Arrangement Agreement with Appili Therapeutics, Targeting September 30 Closing of the Acquisition
July 25, 2024
From
Aditxt, Inc.
Via
Business Wire
Tickers
ADTX
APLIF
OTC
TSX:APLI
Aditxt and Evofem Amend and Restate Merger Agreement, Targeting September 30 Closing
July 17, 2024
From
Aditxt, Inc.
Via
Business Wire
Tickers
ADTX
EVFM
CORRECTING and REPLACING Aditxt Announces Pricing of $4.2 Million Private Placement Priced At-The-Market under Nasdaq Rules
May 03, 2024
From
Aditxt, Inc.
Via
Business Wire
Tickers
ADTX
Aditxt Signs a Definitive Agreement to Acquire Appili Therapeutics Inc., Developer of a Biodefense Vaccine Funded by the U.S. Department of Defense (DoD)
April 02, 2024
From
Aditxt, Inc.
Via
Business Wire
Tickers
ADTX
APLIF
TSX:APLI
Aditxt, Inc. Acquires Proprietary Electroencephalography (EEG) Brain Monitoring Technologies and Devices, Including NeuroCap™ and NeuroEEG™ for Telehealth and Tele-neurology Applications
January 30, 2024
From
Aditxt, Inc.
Via
Business Wire
Tickers
ADTX
< Previous
1
2
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.